FDA Grants Approval to Fruquintinib for Patients With Refractory Metastatic Colorectal Cancer

On November 8, 2023, the US Food and Drug Administration (FDA) approved fruquintinib for patients with metastatic colorectal cancer who had previously been treated with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, an anti-VEGF therapy, and, if appropriate, an anti-EGFR therapy.

Access the full article to read more here.